PortalPublikationenToxicity-reduced, myeloablative allograft followed by lenali...

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.

Standard

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. / Kröger, N; Zabelina, T; Klyuchnikov, E; Kropff, M; Pflüger, K-H; Burchert, A; Stübig, T; Wolschke, C; Ayuketang, Francis Ayuk; Hildebrandt, Y; Bacher, U; Badbaran, A; Schilling, G; Hansen, T; Atanackovic, D; Zander, A R.

in: BONE MARROW TRANSPL, Jahrgang 48, Nr. 3, 3, 2013, S. 403-407.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kröger, N, Zabelina, T, Klyuchnikov, E, Kropff, M, Pflüger, K-H, Burchert, A, Stübig, T, Wolschke, C, Ayuketang, FA, Hildebrandt, Y, Bacher, U, Badbaran, A, Schilling, G, Hansen, T, Atanackovic, D & Zander, AR 2013, 'Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.', BONE MARROW TRANSPL, Jg. 48, Nr. 3, 3, S. 403-407. https://doi.org/10.1038/bmt.2012.142

APA

Kröger, N., Zabelina, T., Klyuchnikov, E., Kropff, M., Pflüger, K-H., Burchert, A., Stübig, T., Wolschke, C., Ayuketang, F. A., Hildebrandt, Y., Bacher, U., Badbaran, A., Schilling, G., Hansen, T., Atanackovic, D., & Zander, A. R. (2013). Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. BONE MARROW TRANSPL, 48(3), 403-407. [3]. https://doi.org/10.1038/bmt.2012.142

Vancouver

Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger K-H, Burchert A et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. BONE MARROW TRANSPL. 2013;48(3):403-407. 3. https://doi.org/10.1038/bmt.2012.142

Bibtex

@article{ac2243d144614c039f3ea2242df9e78f,
title = "Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.",
abstract = "Relapse after dose-reduced allograft in advanced myeloma patients remains high. To reduce the risk of relapse, we investigated a myeloablative toxicity-reduced allograft (aSCT) consisting of i.v. BU and CY followed by lenalidomide maintenance therapy in 33 patients with multiple myeloma (MM) who relapsed following an autograft after a median of 12 months. The cumulative incidence of non-relapse mortality at 1 year was 6% (95% confidence interval (CI): 0-14). After a median interval of 168 days following aSCT, 24 patients started with a median dose of 5 mg (r, 5-15) lenalidomide without dexamethasone. During follow-up, 13 patients discontinued lenalidomide owing to progressive disease (n=6), GvHD (n=3), thrombocytopenia (n=2), or fatigue (n=2). Major toxicities of lenalidomide were GvHD II-III (28%), viral reactivation (16%), thrombocytopenia (III-IV°,16%), neutropenia (III/IV°, 8%), peripheral neuropathy (I/II°, 16%), or other infectious complication (8%). Cumulative incidence of relapse at 3 years was 42% (95% CI: 18-66). The 3-year estimated probability of PFS and OS was 52% (95% CI: 28-76) and 79% (95% CI: 63-95), respectively. Toxicity-reduced myeloablative allograft followed by lenalidomide maintenance is feasible and effective in relapsed patients with MM, but the induction of GvHD should be considered.",
keywords = "Adolescent, Adult, Aged, Angiogenesis Inhibitors, Disease-Free Survival, Female, Humans, Male, Middle Aged, Multiple Myeloma, Recurrence, Salvage Therapy, Stem Cell Transplantation, Thalidomide, Transplantation Conditioning, Transplantation, Homologous, Young Adult",
author = "N Kr{\"o}ger and T Zabelina and E Klyuchnikov and M Kropff and K-H Pfl{\"u}ger and A Burchert and T St{\"u}big and C Wolschke and Ayuketang, {Francis Ayuk} and Y Hildebrandt and U Bacher and A Badbaran and G Schilling and T Hansen and D Atanackovic and Zander, {A R}",
year = "2013",
doi = "10.1038/bmt.2012.142",
language = "English",
volume = "48",
pages = "403--407",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.

AU - Kröger, N

AU - Zabelina, T

AU - Klyuchnikov, E

AU - Kropff, M

AU - Pflüger, K-H

AU - Burchert, A

AU - Stübig, T

AU - Wolschke, C

AU - Ayuketang, Francis Ayuk

AU - Hildebrandt, Y

AU - Bacher, U

AU - Badbaran, A

AU - Schilling, G

AU - Hansen, T

AU - Atanackovic, D

AU - Zander, A R

PY - 2013

Y1 - 2013

N2 - Relapse after dose-reduced allograft in advanced myeloma patients remains high. To reduce the risk of relapse, we investigated a myeloablative toxicity-reduced allograft (aSCT) consisting of i.v. BU and CY followed by lenalidomide maintenance therapy in 33 patients with multiple myeloma (MM) who relapsed following an autograft after a median of 12 months. The cumulative incidence of non-relapse mortality at 1 year was 6% (95% confidence interval (CI): 0-14). After a median interval of 168 days following aSCT, 24 patients started with a median dose of 5 mg (r, 5-15) lenalidomide without dexamethasone. During follow-up, 13 patients discontinued lenalidomide owing to progressive disease (n=6), GvHD (n=3), thrombocytopenia (n=2), or fatigue (n=2). Major toxicities of lenalidomide were GvHD II-III (28%), viral reactivation (16%), thrombocytopenia (III-IV°,16%), neutropenia (III/IV°, 8%), peripheral neuropathy (I/II°, 16%), or other infectious complication (8%). Cumulative incidence of relapse at 3 years was 42% (95% CI: 18-66). The 3-year estimated probability of PFS and OS was 52% (95% CI: 28-76) and 79% (95% CI: 63-95), respectively. Toxicity-reduced myeloablative allograft followed by lenalidomide maintenance is feasible and effective in relapsed patients with MM, but the induction of GvHD should be considered.

AB - Relapse after dose-reduced allograft in advanced myeloma patients remains high. To reduce the risk of relapse, we investigated a myeloablative toxicity-reduced allograft (aSCT) consisting of i.v. BU and CY followed by lenalidomide maintenance therapy in 33 patients with multiple myeloma (MM) who relapsed following an autograft after a median of 12 months. The cumulative incidence of non-relapse mortality at 1 year was 6% (95% confidence interval (CI): 0-14). After a median interval of 168 days following aSCT, 24 patients started with a median dose of 5 mg (r, 5-15) lenalidomide without dexamethasone. During follow-up, 13 patients discontinued lenalidomide owing to progressive disease (n=6), GvHD (n=3), thrombocytopenia (n=2), or fatigue (n=2). Major toxicities of lenalidomide were GvHD II-III (28%), viral reactivation (16%), thrombocytopenia (III-IV°,16%), neutropenia (III/IV°, 8%), peripheral neuropathy (I/II°, 16%), or other infectious complication (8%). Cumulative incidence of relapse at 3 years was 42% (95% CI: 18-66). The 3-year estimated probability of PFS and OS was 52% (95% CI: 28-76) and 79% (95% CI: 63-95), respectively. Toxicity-reduced myeloablative allograft followed by lenalidomide maintenance is feasible and effective in relapsed patients with MM, but the induction of GvHD should be considered.

KW - Adolescent

KW - Adult

KW - Aged

KW - Angiogenesis Inhibitors

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Recurrence

KW - Salvage Therapy

KW - Stem Cell Transplantation

KW - Thalidomide

KW - Transplantation Conditioning

KW - Transplantation, Homologous

KW - Young Adult

U2 - 10.1038/bmt.2012.142

DO - 10.1038/bmt.2012.142

M3 - SCORING: Journal article

C2 - 22863722

VL - 48

SP - 403

EP - 407

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 3

M1 - 3

ER -